Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 11
2021 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
The advantages and risks of ruxolitinib for the treatment of polycythemia vera.
Colafigli G, Scalzulli E, Pepe S, Di Prima A, Efficace F, Martelli M, Foà R, Breccia M. Colafigli G, et al. Among authors: di prima a. Expert Rev Hematol. 2020 Oct;13(10):1067-1072. doi: 10.1080/17474086.2020.1816819. Epub 2020 Sep 11. Expert Rev Hematol. 2020. PMID: 32873088 Review.
Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?
Colafigli G, Scalzulli E, Di Prima A, Pepe S, Loglisci MG, Diverio D, Martelli M, Foà R, Breccia M. Colafigli G, et al. Among authors: di prima a. Crit Rev Oncol Hematol. 2021 Jan;157:103163. doi: 10.1016/j.critrevonc.2020.103163. Epub 2020 Nov 12. Crit Rev Oncol Hematol. 2021. PMID: 33246263 Review.
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up.
Scalzulli E, Colafigli G, Pepe S, De Luca G, Di Prima A, Efficace F, Diverio D, Latagliata R, Martelli M, Foà R, Breccia M. Scalzulli E, et al. Among authors: di prima a. Leuk Lymphoma. 2021 Apr;62(4):1026-1027. doi: 10.1080/10428194.2020.1808205. Epub 2020 Aug 16. Leuk Lymphoma. 2021. PMID: 32799601 No abstract available.
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.
Scalzulli E, Caocci G, Efficace F, Rizzo L, Colafigli G, Di Prima A, Pepe S, Fegatelli DA, Carmosino I, Diverio D, Latagliata R, La Nasa G, Martelli M, Foà R, Breccia M. Scalzulli E, et al. Among authors: di prima a. Ann Hematol. 2021 May;100(5):1213-1219. doi: 10.1007/s00277-021-04477-0. Epub 2021 Mar 7. Ann Hematol. 2021. PMID: 33677654
Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy.
Porrazzo M, Nicolai E, Riminucci M, Vitale C, Coscia M, De Paoli L, Rago A, Buscicchio G, Maestrini G, Ligia S, Di Prima A, Corsi A, Caronna R, Gaidano G, Mauro FR. Porrazzo M, et al. Among authors: di prima a. Cancers (Basel). 2020 Jul 3;12(7):1773. doi: 10.3390/cancers12071773. Cancers (Basel). 2020. PMID: 32635175 Free PMC article.
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort.
Chiatamone Ranieri S, Arleo MA, Trasarti S, Bizzoni L, Carmosino I, De Luca ML, Mohamed S, Mariggiò E, Scalzulli E, Rosati S, De Benedittis D, Colafigli G, Pepe S, Molica M, Scamuffa MC, Di Prima A, Ferretti A, Baldacci E, Mancini M, Santoro C, Vignetti M, Breccia M, Latagliata R. Chiatamone Ranieri S, et al. Among authors: di prima a. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e328-e333. doi: 10.1016/j.clml.2020.11.003. Epub 2020 Nov 6. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33342728
14 results